Cargando…

Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies

BACKGROUND: KW-2478 is a novel, non-ansamycin, non-purine heat-shock protein 90 (Hsp90) inhibitor. METHODS: In this phase I, multicentre study, KW-2478 was administered intravenously over 1 h at doses ranging from 14 to 176 mg m(–2) once daily on days 1–5 of a 14-day cycle in a standard 3+3 design i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yong, K, Cavet, J, Johnson, P, Morgan, G, Williams, C, Nakashima, D, Akinaga, S, Oakervee, H, Cavenagh, J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4716540/ https://www.ncbi.nlm.nih.gov/pubmed/26695442 http://dx.doi.org/10.1038/bjc.2015.422

Ejemplares similares

A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma
por: Cavenagh, J, et al.
Publicado: (2017)

Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib
por: Ishii, T, et al.
Publicado: (2012)

The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
por: Zeng, Dachuan, et al.
Publicado: (2022)

Preclinical and phase I clinical studies of KW-2450, a dual IGF-1R/IR tyrosine kinase inhibitor, in combination with lapatinib and letrozole
por: Umehara, Hiroshi, et al.
Publicado: (2018)

Preclinical and first‐in‐human phase I studies of KW‐2450, an oral tyrosine kinase inhibitor with insulin‐like growth factor receptor‐1/insulin receptor selectivity
por: Schwartz, Gary K., et al.
Publicado: (2016)

Inhibitors of HSP90 in melanoma
por: Mielczarek-Lewandowska, Aleksandra, et al.
Publicado: (2019)

HSP90 inhibitors disrupt a transient HSP90-HSF1 interaction and identify a noncanonical model of HSP90-mediated HSF1 regulation
por: Kijima, Toshiki, et al.
Publicado: (2018)

Hsp90 Inhibitors Prevent HSV-1 Replication by Directly Targeting UL42-Hsp90 Complex
por: Qin, Shurong, et al.
Publicado: (2022)

Phase I Evaluation of STA-1474, a Prodrug of the Novel HSP90 Inhibitor Ganetespib, in Dogs with Spontaneous Cancer
por: London, Cheryl A., et al.
Publicado: (2011)

Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2014)

Mps1 Mediated Phosphorylation of Hsp90 Confers Renal Cell Carcinoma Sensitivity and Selectivity to Hsp90 Inhibitors
por: Woodford, Mark R., et al.
Publicado: (2016)

Upregulation of TGF-β-induced HSP27 by HSP90 inhibitors in osteoblasts
por: Kuroyanagi, Gen, et al.
Publicado: (2022)

Hsp90 Inhibitors for the Treatment of Chronic Myeloid Leukemia
por: Khajapeer, Kalubai Vari, et al.
Publicado: (2015)

Hsp90 Inhibitor Can Inhibit UV-Carcinogenesis
por: Katiyar, Santosh K.
Publicado: (2015)

Circumventing HSP90 inhibitors via apoptosis block
por: Fennell, Dean A., et al.
Publicado: (2015)

Identification and characterization of the antiplasmodial activity of Hsp90 inhibitors
por: Murillo-Solano, Claribel, et al.
Publicado: (2017)

Inhibition of the NLRP3 inflammasome by HSP90 inhibitors
por: Nizami, Sohaib, et al.
Publicado: (2020)

The Role of HSP90 Inhibitors in the Treatment of Cardiovascular Diseases
por: Qi, Shiyu, et al.
Publicado: (2022)

The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1
por: Usmani, Saad Z, et al.
Publicado: (2010)

2478. Surveillance of antibacterial resistance among clinical isolates from hospitals in Shanghai: results of 2018
por: Yang, Yang, et al.
Publicado: (2019)

PB2478: ASCIMINIB INDUCES ERYTHROPOIESIS IN CHRONIC MYELOID LEUKEMIA CELLS THROUGH DIFFERENTIATION AND NOT BY SELECTION
por: Hassan, Hammad, et al.
Publicado: (2023)

Identification of HSP90 inhibitors as a novel class of senolytics
por: Fuhrmann-Stroissnigg, Heike, et al.
Publicado: (2017)

A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies
por: Goldman, Jonathan W, et al.
Publicado: (2013)

Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors
por: Gillis, Joanna L., et al.
Publicado: (2013)

The Ribosomal Biogenesis Protein Utp21 Interacts with Hsp90 and Has Differing Requirements for Hsp90-Associated Proteins
por: Tenge, Victoria R., et al.
Publicado: (2014)

Hsp90 inhibitor induces autophagy and apoptosis in osteosarcoma cells
por: MORI, MASAKI, et al.
Publicado: (2014)

Molecular Dynamics Simulations of Hsp90 with an Eye to Inhibitor Design
por: Moroni, Elisabetta, et al.
Publicado: (2012)

Silibinin, an HSP90 Inhibitor, on Human ACTH-Secreting Adenomas
por: Pecori Giraldi, Francesca, et al.
Publicado: (2023)

Unleashing the full potential of Hsp90 inhibitors as cancer therapeutics through simultaneous inactivation of Hsp90, Grp94, and TRAP1
por: Park, Hye-Kyung, et al.
Publicado: (2020)

High-Throughput Screen of Natural Product Libraries for Hsp90 Inhibitors
por: Davenport, Jason, et al.
Publicado: (2014)

Circulating heat shock protein 90 (Hsp90) and autoantibodies to Hsp90 are increased in patients with atopic dermatitis
por: Sitko, Krzysztof, et al.
Publicado: (2021)

Efficacy of an HSP90 inhibitor, ganetespib, in preclinical thyroid cancer models
por: Lin, Shu-Fu, et al.
Publicado: (2017)

NVP-AUY922, a novel HSP90 inhibitor, inhibits the progression of malignant pheochromocytoma in vitro and in vivo
por: Lian, Jianpo, et al.
Publicado: (2017)

Y‐632 inhibits heat shock protein 90 (Hsp90) function by disrupting the interaction between Hsp90 and Hsp70/Hsp90 organizing protein, and exerts antitumor activity in vitro and in vivo
por: Wang, Wenqian, et al.
Publicado: (2016)

The broad stroke of Hsp90 inhibitors: painting over the RAF inhibitor paradox
por: Vido, Michael, et al.
Publicado: (2015)

Targeting HSP90 for cancer therapy
por: Mahalingam, D, et al.
Publicado: (2009)

Immunotherapeutic targeting of HSP90 client proteins in BRAF-inhibitor resistant melanoma
por: Fecek, Ronald J, et al.
Publicado: (2015)

Potent antitumor activity of the novel HSP90 inhibitors AUY922 and HSP990 in neuroendocrine carcinoid cells
por: ZITZMANN, KATHRIN, et al.
Publicado: (2013)

Elevated expression of HSP90 and the antitumor effect of an HSP90 inhibitor via inactivation of the Akt/mTOR pathway in undifferentiated pleomorphic sarcoma
por: Bekki, Hirofumi, et al.
Publicado: (2015)

Hsp-90 and the biology of nematodes
por: Him, Nik AIIN, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_v4ncvc9qlvl06ttgh3l0rqkqj0